Veradermics, Incorporated is a late clinical-stage biopharmaceutical company. The Company is focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Its initial focus is developing better treatments for pattern hair loss (PHL). The Company is developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL to reduce the barriers to wide adoption of chronic hair loss therapy and potentially transform PHL treatment. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent, designed to maximize minoxidil’s impact on hair restoration while minimizing the risk of cardiac activity. The Company is conducting a Phase II clinical trial evaluating VDPHL01 in male and female patients with mild-to-moderate PHL.
Ticker SymbolMANE
Company nameVeradermics Inc
IPO dateFeb 04, 2026
CEOWaldman (Reid Alexander)
Number of employees19
Security typeOrdinary Share
Fiscal year-endFeb 04
Address- -
City- -
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
Country- -
Postal code- -
Phone- -
Website- -
Ticker SymbolMANE
IPO dateFeb 04, 2026
CEOWaldman (Reid Alexander)
A total of
0.00
USD has been distributed in dividends over the past 5 years.

No Data